In this article, we will discuss Olaparib (Clinical Trials Experience-5). So, let’s get started.
Adverse reactions led to dose interruptions in 35% of those receiving Olparib and 10% of those receiving placebo; dose reductions in 26% of Olparib and 4% of placebo; and discontinuation in 6% of Olparib and 2% in placebo.